Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns?

Teleflex Incorporated TFX has moved a major piece of its portfolio reset from plan to execution. The August 2026 sale of its OEM business brought in $1.5 billion in cash, giving the company immediate capacity to reduce debt and continue returning capital to shareholders.

The financial effect is already visible. Teleflex raised its 2026 adjusted earnings outlook even as it cut its underlying revenue-growth forecast, shifting the near-term investment case toward capital allocation and balance-sheet improvement rather than faster operating growth.

How Teleflex's OEM Sale Strengthens the Balance Sheet

Teleflex estimates after-tax proceeds from the OEM sale at about $1.25 billion. It used the proceeds primarily to repay roughly $700 million of Term Loan A-2 debt tied to the Vascular Intervention acquisition and to replenish funds used for second-quarter share repurchases.

That action reduced pro forma net leverage to about 1.9X from 2.8X at second-quarter end. The lower debt load should improve financial flexibility and help reduce interest expense as Teleflex continues its broader plan to cut debt by about $800 million using strategic-divestiture proceeds.

Why TFX Raised Its 2026 EPS Guidance

Teleflex lifted 2026 adjusted earnings guidance to $6.90-$7.20 from $6.25-$6.55. The new range reflects second-quarter results, the benefit of second-quarter share repurchases and lower expected net interest expense.

Image Source: Zacks Investment Research

The company repurchased about 1.9 million shares for $250 million during the second quarter and planned a $250 million accelerated share repurchase effective Aug. 7. The raised EPS range does not include the anticipated benefit from that accelerated repurchase or other expected second-half buybacks, leaving additional capital deployment outside the current guidance.

What Teleflex Still Must Complete in 2026

The Acute Care and Interventional Urology divestiture remains unfinished. Teleflex expects the transaction to close in the fourth quarter of 2026, subject to regulatory approval, after the Federal Trade Commission issued a second request in March.

Separation costs totaled $29 million in the second quarter and $59.2 million in the first half. Teleflex expects transition and manufacturing service agreements tied to the pending sale to help offset stranded costs on an annualized basis, while a restructuring program targets about $50 million of annual pretax savings by mid-2028.

How TFX's Margin Pressure Complicates the Upside

Capital-allocation benefits are arriving while core profitability remains under pressure. Second-quarter adjusted gross margin fell 280 basis points to 61.7%, reflecting tariffs and the lower gross-margin profile of the acquired Vascular Intervention business. Adjusted operating margin declined 520 basis points to 19.6% as acquisition-related operating costs and higher R&D spending added pressure.

Teleflex expects adjusted operating margin of about 19% for 2026. In vascular access, Becton, Dickinson and Company BDX remains a relevant peer after launching its CentroVena One central venous catheter insertion system in April 2026. Boston Scientific Corporation BSX provides another comparison in interventional markets through its interventional cardiology and peripheral interventions portfolios.

Teleflex's Signals Support a Balanced View

The OEM sale improves the balance sheet and supports a higher earnings outlook, but 2026 remains a transition year. Teleflex also lowered pro forma adjusted constant currency revenue-growth guidance to 3.5%-4.5% from 4.5%-5.5%, underscoring that capital-allocation benefits are emerging faster than a clean acceleration in operating growth.

Image Source: Zacks Investment Research

TFX currently carries a Zacks Rank #2 (Buy). Its Value Score of B, Momentum Score of B and VGM Score of B add favorable style characteristics to that short-term earnings-revision signal, while its Growth Score of C points to a more moderate growth profile. That mix supports a constructive but measured view as the remaining divestiture, integration work and margin recovery progress.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research